Med-Immune Science Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 32

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $21.5M

  • Investors
  • 7

Med-Immune Science General Information

Description

Manufacturer of biopharmaceutical drugs intended to advance the development of macromolecular therapies for cancer and immune-related disorders. The company offers antibody discovery platforms and macrophage target validation technologies, enabling medical researchers and oncology specialists to accelerate therapeutic innovation and enhance patient care.

Contact Information

Website
www.medimscience.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 1301, Building 3
  • Number 18 Zhiheng Lane, Xiaoshan District
  • Hangzhou, Zhejiang
  • China
+86 0571
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Manufacturing, Life Sciences, Oncology
Corporate Office
  • Room 1301, Building 3
  • Number 18 Zhiheng Lane, Xiaoshan District
  • Hangzhou, Zhejiang
  • China
+86 0571

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Med-Immune Science Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 03-Feb-2026 $21.5M Completed Generating Revenue
2. Early Stage VC 02-Sep-2022 Completed Generating Revenue
1. Early Stage VC 02-Jul-2021 Completed Generating Revenue
To view Med-Immune Science’s complete valuation and funding history, request access »

Med-Immune Science Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Med-Immune Science Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bayland Capital Corporate Venture Capital Minority
Hongfeng Capital Growth/Expansion Minority
Jiangsu Winfast Investment Asset Manager Minority
Shanghai Industrial Capital Management Growth/Expansion Minority
Ming Bioventures Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

Med-Immune Science FAQs

  • When was Med-Immune Science founded?

    Med-Immune Science was founded in 2019.

  • Where is Med-Immune Science headquartered?

    Med-Immune Science is headquartered in Hangzhou, China.

  • What is the size of Med-Immune Science?

    Med-Immune Science has 32 total employees.

  • What industry is Med-Immune Science in?

    Med-Immune Science’s primary industry is Drug Discovery.

  • Is Med-Immune Science a private or public company?

    Med-Immune Science is a Private company.

  • What is Med-Immune Science’s current revenue?

    The current revenue for Med-Immune Science is .

  • How much funding has Med-Immune Science raised over time?

    Med-Immune Science has raised $21.5M.

  • Who are Med-Immune Science’s investors?

    Bayland Capital, Hongfeng Capital, Jiangsu Winfast Investment, Shanghai Industrial Capital Management, and Ming Bioventures are 5 of 7 investors who have invested in Med-Immune Science.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process